百花医药 2025年第一次临时股东大会法律意见书 新疆星河井然律师事务所 新疆星河井然律师事务所 关于新疆百花村医药集团股份有限公司 2025年第一次临时股东大会的 律师见证法律意见书 星河证股字[2025]第006号 致:新疆百花村医药集团股份有限公司 新疆星河井然律师事务所 准确、完整,相关副本或复印件与原件一致,所发布或提供的文件不存在 虚假记载、误导性陈述或者重大遗漏。 (4)本所及本所律师同意将本法律意见书作为公司本次会议的必备文 件予以公告,未经本所及本所律师事先书面同意,任何人不得将其用作其 他任何目的。 新疆星河井然律师事务所(以下简称"本所")接受新疆百花村医药 集团股份有限公司(以下简称"公司")的委托,指派本所律师出席公司 2025年第一次临时股东大会(以下简称"本次股东大会"),并根据《中 华人民共和国公司法》(以下简称"公司法")、《中华人民共和国证券 法》《上市公司股东大会规则》等现行法律、法规、规范性文件和《新疆 百花村医药集团股份有限公司》(以下简称"公司章程")的有关规定出 具本法律意见书。 关于本法律意见书,本所及本所律师谨作如下声明: (1) 本所及本所律师本次所发表的法 ...

新疆百花村医药集团股份有限公司 证券代码：600721 证券简称：百花医药 公告编号：2025-036 新疆百花村医药集团股份有限公司 2025年第一次临时股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 (一) 股东大会召开的时间：2025 年 09 月 08 日 (二) 股东大会召开的地点：新疆百花村医药集团股份有限公司 22 楼会议室 (三) 出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： | 1、出席会议的股东和代理人人数 | 194 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 128,030,783 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股份总数的比例（%） | 33.2938 | (四) 本次股东大会的召集和召开、表决方式符合《公司法》《公司章程》等 法律、法规及规范性文件的规定。本次会议采取现场加网络投票方式，公司董事 长郑彩红女士主持会议。 (五) ...

Market Overview - As of September 4, the Shanghai Composite Index closed at 3765.88 points, with a decline of 1.25%. The Shenzhen Component Index closed at 12118.70 points, down 2.83%, and the ChiNext Index closed at 2776.25 points, decreasing by 4.25% [1] Trading Activity - A total of 2131 stocks saw an increase in average transaction volume, with 40 stocks experiencing a rise of over 50% in average transaction volume. Conversely, 2426 stocks reported a decrease in average transaction volume [1] - Notable stocks with significant increases in average transaction volume include Aishida (爱仕达) with a 207.02% increase, Huijia Times (汇嘉时代) with 184.35%, and Victory Precision (胜利精密) with 158.81% [1] Active Stocks - The stocks with the highest increase in transaction volume and transaction count include: - Spring兴精工 with a transaction count increase of 2190.85% - Hanzhong Precision (汉钟精机) with a transaction count increase of 827.07% - Lushan New Materials (鹿山新材) with a transaction count increase of 476.62% [1] Notable Performers - The following stocks showed significant daily gains: - Aishida (爱仕达) increased by 10.03% - Huijia Times (汇嘉时代) rose by 10.05% - Victory Precision (胜利精密) gained 10.09% [1] - Other notable performers include: - Strait Environmental (海峡环保) with a 10.08% increase - An彩高科 with a 9.92% increase [1] Additional Trading Insights - The average transaction volume and transaction count for several stocks also showed substantial increases, indicating heightened trading activity. For example, Tianchuang Fashion (天创时尚) had a transaction count increase of 204.19% [1][2]

Core Points - Baihua Pharmaceutical (600721) experienced a stock price increase of 6.24% with a turnover rate of 35.69% and a trading volume of 1.463 billion yuan, indicating significant market activity [2] - The stock was listed on the Shanghai Stock Exchange due to its high turnover rate, with a net selling amount of 57.5752 million yuan from brokerage seats [2] - The top five brokerage seats accounted for a total transaction amount of 302 million yuan, with a buying amount of 122 million yuan and a selling amount of 180 million yuan, resulting in a net selling of 57.5752 million yuan [2] Trading Data - The largest buying brokerage was Guotai Junan Securities Co., Ltd. Shanghai Changning District Jiangsu Road Securities Office, with a buying amount of 36.5685 million yuan [2] - The largest selling brokerage was Kaiyuan Securities Co., Ltd. Xi'an West Street Securities Office, with a selling amount of 60.8128 million yuan [2] - The stock saw a net inflow of 54.0097 million yuan from main funds, with a significant inflow of 62.8722 million yuan from large orders, while large orders saw a net outflow of 8.8626 million yuan [2] Financial Performance - For the first half of the year, Baihua Pharmaceutical reported a total revenue of 202 million yuan, representing a year-on-year growth of 2.95% [2] - The net profit for the same period was 25.4834 million yuan, showing a year-on-year increase of 12.45% [2]

Group 1 - Baihua Pharmaceutical has experienced a stock price surge, reaching a limit up and achieving a consecutive two-day increase [2] - The cumulative increase over the past two days is reported at 21.01% [2]

Core Viewpoint - Baihua Pharmaceutical (600721) experienced a trading surge, reaching the daily limit with a turnover rate of 9.48% and a transaction volume of 370 million yuan, indicating strong market interest and activity [2]. Trading Activity - The stock was listed on the Shanghai Stock Exchange due to a price deviation of 11.19%, with a net buying amount of 74.85 million yuan from brokerage seats [2]. - The top five brokerage seats accounted for a total transaction volume of 163 million yuan, with a buying amount of 119 million yuan and a selling amount of 44.15 million yuan, resulting in a net buying of 74.85 million yuan [2]. - The largest buying brokerage was Kaiyuan Securities, which purchased 60.13 million yuan, while the largest selling brokerage was Guotai Junan Securities, which sold 13.35 million yuan [2]. Fund Flow - The stock saw a net inflow of 109 million yuan from major funds, with a significant inflow of 115 million yuan from large orders, while smaller orders experienced a net outflow of 5.72 million yuan [2]. - Over the past five days, the net inflow of major funds totaled 161 million yuan [2]. Financial Performance - On August 22, the company reported its semi-annual results, achieving a revenue of 202 million yuan, representing a year-on-year growth of 2.95%, and a net profit of 25.48 million yuan, reflecting a year-on-year increase of 12.45% [2].

Market Performance - The Artemisinin concept index rose by 0.17%, ranking third among concept sectors, with three stocks increasing in value, including Baihua Medicine which hit the daily limit, and Fosun Pharma and China Resources Sanjiu which rose by 0.39% and 0.05% respectively [1] - The top gainers in the Artemisinin sector were Baihua Medicine, Fosun Pharma, and China Resources Sanjiu, while the biggest losers included Delong Huineng, New Harmony, and Zhejiang Medicine, which fell by 3.33%, 1.18%, and 1.17% respectively [1] Capital Flow - The Artemisinin concept sector experienced a net outflow of 58 million yuan in main capital, with Baihua Medicine receiving the highest net inflow of 109 million yuan, followed by China Resources Sanjiu and Zhejiang Medicine with net inflows of 14.16 million yuan and 5.79 million yuan respectively [2] - The net inflow ratios for Baihua Medicine, China Resources Sanjiu, and Zhejiang Medicine were 29.47%, 5.98%, and 2.65% respectively, indicating strong interest in these stocks [3] Stock Performance Details - Baihua Medicine had a daily increase of 10.03% with a turnover rate of 9.48% and a main capital flow of 108.91 million yuan, leading the sector [3] - Other notable stocks included China Resources Sanjiu with a slight increase of 0.05% and a turnover rate of 1.18%, and Zhejiang Medicine which decreased by 1.17% with a turnover rate of 1.48% [3][4]

Market Overview - The Shanghai Composite Index fell by 0.96% to 3820.98 points, while the Shenzhen Component Index decreased by 0.63% to 12474.44 points. The ChiNext Index remained flat at 2872.11 points [3][4] - The total trading volume in the Shanghai and Shenzhen markets reached 1.45 trillion yuan, with over 4300 stocks declining and nearly 1000 stocks rising [3] Sector Performance - The gaming and film sectors showed strong performance, with notable gains in stocks such as Chengdu Xian Dao, which rose over 10%, and other pharmaceutical companies like Baihua Medicine and Renfu Medicine hitting the daily limit [4][5] - The robotics sector also performed well, with stocks like Zhejiang Rongtai and Qin Chuan Machine Tool experiencing significant increases [7][8] Key Stock Movements - Chengdu Xian Dao increased by 10.43% to 28.03 yuan, while Baihua Medicine rose by 10.03% to 10.42 yuan [5] - The gold sector saw a rise, with spot gold prices surpassing $3545 per ounce, marking a new high [12] Economic Indicators - The People's Bank of China conducted a reverse repurchase operation of 229.1 billion yuan at an interest rate of 1.40%, unchanged from previous rates [10]

Group 1 - The innovative drug concept is experiencing a rebound, with significant stock price increases observed [1] - Baihua Pharmaceutical (600721) and Renfu Pharmaceutical (600079) have reached the daily limit increase [1] - Boteng Co., Ltd. (300363), Rejing Bio, and Heng Rui Pharmaceutical (600276) are among the top gainers in terms of percentage increase [1]

Core Viewpoint - The company Xinjiang Baihua Village Pharmaceutical Group Co., Ltd. is proposing to cancel its supervisory board and amend its articles of association and related rules to enhance corporate governance and comply with updated legal regulations [3][4][5]. Group 1: Proposal Details - The proposal to cancel the supervisory board is based on the need to align with the latest legal requirements and improve the company's governance structure [3][4]. - The supervisory board's responsibilities will be transferred to the audit committee of the board of directors [3]. - The amendments to the articles of association aim to further refine corporate governance and adapt to the operational needs of a listed company [4][5]. Group 2: Amendments to Articles of Association - The registered capital of the company has been updated from RMB 384,032,635 to RMB 384,547,635 [6]. - The company will no longer accept its own shares as collateral [7]. - The provisions regarding the transfer of shares by major shareholders and management have been revised to enhance transparency and compliance [8][9]. Group 3: Shareholder Rights and Responsibilities - Shareholders are entitled to various rights, including profit distribution and participation in decision-making processes [8][9]. - The company emphasizes the importance of shareholders adhering to the articles of association and legal obligations [12][14]. - Major shareholders must report any pledging of shares to the company promptly [13][15].